The World Health Organization has worked to speed up the use of some experimental vaccines and companies are ramping up testing. Earlier this month NewLink Genetics said it would start safety testing of a vaccine within a few weeks, while Inovio Pharmaceuticals said it would start human trials of a DNA-based vaccine in early 2015.
Read MoreThere won't be an Ebola outbreak in US: Virologist
Shares of Inovio Pharmaceuticals shares rose 35 cents, or 3.6 percent, to $10.20 in aftermarket trading, while NewLink Genetics shares gained $2.68, or 12.5 percent, to $24.10. Stock of some other companies that have been involved in efforts to come up with vaccines and medications also jumped. BioCryst Pharmaceuticals added $1.26, or 13 percent, to $11.04; Sarepta Therapeutics rose $1.57, or 7.4 percent, to $22.67; and Tekmira Pharmaceuticals stock climbed $5.97, or 28 percent, to $27.11.
Read More100 doses of Ebola drug available: Sarepta CEO